Patents Assigned to THERAPEUTICS, INC.
  • Methods and compositions for treating trinucleotide repeat disorders
    Patent number: 10646543
    Abstract: Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: May 12, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Edward J. Rebar, H. Steve Zhang
  • Heterocyclic degronimers for target protein degradation
    Patent number: 10646575
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 12, 2020
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
  • Methods of manufacture of therapeutic products comprising vitalized placental dispersions
    Patent number: 10646519
    Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: May 12, 2020
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
  • Tripeptide epoxy ketone protease inhibitors
    Patent number: 10647744
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: May 12, 2020
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
  • Uses of indolinone compounds
    Patent number: 10646470
    Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 12, 2020
    Assignee: Oncternal Therapeutics, Inc.
    Inventors: Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
  • Method of treating mucopolysaccharidosis type I or II
    Patent number: 10648001
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 12, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Punctal Plug With Active Agent
    Publication number: 20200138701
    Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.
    Type: Application
    Filed: March 21, 2019
    Publication date: May 7, 2020
    Applicant: Mati Therapeutics Inc.
    Inventors: Steven A. Odrich, Liane C. Glazer
  • N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
    Publication number: 20200140456
    Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
  • ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20200140417
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: November 13, 2019
    Publication date: May 7, 2020
    Applicant: Linnaeus Therapeutics, Inc.
    Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
  • SYSTEM AND METHOD FOR OPTOGENETIC THERAPY
    Publication number: 20200139151
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: January 15, 2020
    Publication date: May 7, 2020
    Applicant: Circuit Therapeutics, Inc.
    Inventors: David C. Lundmark, Fred Moll, Alexander K. Arrow
  • sGC stimulators
    Patent number: 10639308
    Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: May 5, 2020
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
  • Glucocerebroside treatment of disease
    Patent number: 10639324
    Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: May 5, 2020
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
  • Artificial nucleases including engineered FokI cleavage half-domains
    Patent number: 10640790
    Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: May 5, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Yannick Doyon, Jeffrey C. Miller
  • Methods and compositions for engineering immunity
    Patent number: 10639383
    Abstract: Nucleases and methods of using these nucleases for expressing an antibody from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: May 5, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Brigit E. Riley
  • DELIVERY TUBE AND METHODS FOR TRANSPORTING PARTICLES INTO THE RESPIRATORY SYSTEM
    Publication number: 20200129716
    Abstract: Apparatus for transporting particles through a patient's trachea into the respiratory system include a delivery tube having at least a ventilation lumen and a particle delivery lumen. The delivery tube has a centering device near its distal tip, such as a balloon eccentrically mounted on the tube to position an outlet of the particle delivery lumen near a centerline of the trachea above the carina branching into the right and left bronchus. A proximal end of the delivery tube connects to a source of particles, and a controller may be provided to adjust a rate and/or an amount of the particles delivered to the patient. In a specific example, frozen particles are delivered to control core body temperature. In other instances, the particle may be a medicament or other substance for effecting other therapies or diagnostic procedures.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 30, 2020
    Applicant: Qool Therapeutics, Inc.
    Inventor: Michael J. Horzewski
  • NOVEL EGFR MODULATORS AND USES THEREOF
    Publication number: 20200129516
    Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
    Type: Application
    Filed: September 30, 2019
    Publication date: April 30, 2020
    Applicant: ACEA Therapeutics, Inc.
    Inventors: Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
  • PERSONALIZED CONTRACEPTIVE FORMULATIONS
    Publication number: 20200129524
    Abstract: Formulations, kits and methods for effecting contraception are disclosed. These formulations, kits and methods involve the delivery of progestins and estrogens in amounts personalized to the body weight and or the BMI of the women receiving the treatment.
    Type: Application
    Filed: March 13, 2018
    Publication date: April 30, 2020
    Applicant: Agile Therapeutics, Inc.
    Inventors: Agis KYDONIEUS, Elizabeth I.O. Garner, Joseph A. Chiodo, III, Joseph A. D'Urso
  • Methods and Compositions for Promoting Immune Cell Function
    Publication number: 20200131239
    Abstract: The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.
    Type: Application
    Filed: June 13, 2017
    Publication date: April 30, 2020
    Applicant: Torque Therapeutics, Inc.
    Inventors: Ferdinando PUCCI, Thomas Lars ANDRESEN, Douglas Scott JONES, Ulrik NIELSEN, James Andrew RAKESTRAW
  • MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
    Publication number: 20200129378
    Abstract: The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies.
    Type: Application
    Filed: June 26, 2019
    Publication date: April 30, 2020
    Applicant: Aimmune Therapeutics, Inc.
    Inventors: Bryan WALSER, Howard V. RAFF
  • Mounting cradle
    Patent number: D884165
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: May 12, 2020
    Assignee: SPR Therapeutics, Inc.
    Inventors: Matthew G. deBock, Joseph W. Boggs, II, Matthew J. Wunzin, Robert B. Strother, Jr., Devin Sell, Mark R. Stultz, Bradley A. Lewis